CeriBell, Inc. (CBLL) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of CeriBell, Inc. and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBLL
CeriBell, Inc.
$24.67HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
MLTX
MoonLake Immunotherapeutics
$11.06HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — CBLL vs MLTX
growth of $100 · dividends reinvested · last 2yCBLL -0.6% (-0.3%/yr)MLTX -76.7% (-51.8%/yr)CBLL compounded faster over this window
CBLL MLTX
CBLL vs MLTX: by the numbers
- •CBLL is the larger company ($936M vs $930M market cap).
- •Both run net losses; MLTX's is the smaller (0.00% vs -64.73% net margin).
Metrics side by side
Valuation
| Metric | CBLL | MLTX |
|---|---|---|
| P/S ratio | 9.18 | N/A |
| P/B ratio | 7.29 | 2.17 |
Profitability
| Metric | CBLL | MLTX |
|---|---|---|
| Gross margin | 88.90% | 0.00% |
| Operating margin | -68.62% | 0.00% |
| Net margin | -64.73% | 0.00% |
| ROE | -51.43% | -61.58% |
| ROIC | -46.54% | -50.77% |
Growth (annualized)
| Metric | CBLL | MLTX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 2.81% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.